Study Summary
This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD19 CAR-T cell in the treatment of recurrent or refractory B-ALL
Want to learn more about this trial?
Request More InfoInterventions
CD19 CAR-TBIOLOGICAL
Biological: CD19 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Hebei yanda Ludaopei Hospital | Hebei | Sanhe | China |
| BeiJing Ludaopei Hospital | Beijing | Yizhuang | China |